EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Efficacy and Safety of Denosumab and Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis—A Comparative Study of Bone Metabolism, Bone Density, and Sex Hormone Levels

Huiling Tang, Jinyan Chen, Xufeng Fan iD

Journal of Applied Toxicology · 2025

DOI: 10.1002/jat.4967 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Applied Toxicology, 2025. Verfasst von Huiling Tang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical, Foresea Life Insurance Guangxi Hospital, Nanning, China. Hauptthemen laut MEDLINE: Denosumab, Bone Density, Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To analyze and compare the effects of zoledronic acid (Aclasta) and denosumab (Prolia) treatment on sex hormones, bone mineral density (BMD), 25‐hydroxyvitamin D (25(OH)D), procollagen type 1 N‐terminal propeptide (P1NP), beta‐CrossLaps (β‐CTX), and adverse effects. Eighty postmenopausal women with osteoporosis were consecutively enrolled and then randomly assigned to two groups: 40 received zoledronic acid plus standard care (control group) and 40 received denosumab plus standard care (research group). Outcomes included sex hormone levels, BMD (lumbar spine, hip, and femoral neck), bone metabolism markers (25(OH)D, P1NP, and β‐CTX), and adverse reactions, assessed over 1 year. No significant differences in luteinizing hormone, follicle‐stimulating hormone, or estradiol levels were observed between the groups before and after treatment ( p > 0.05). The baseline BMD and bone marker levels were similar between the groups ( p > 0.05). After 6 months and 1 year, the denosumab group showed significantly higher BMD and 25(OH)D levels and lower P1NP and β‐CTX levels than the zoledronic acid group ( p < 0.05). Adverse reactions were less frequent with denosumab (2.5%) than with zoledronic acid (27.5%) ( p < 0.05). Zoledronic acid and denosumab have comparable effects on sex hormone regulation. Denosumab has demonstrated superior improvements in BMD, bone metabolism, and safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBone DensityOsteoporosis, PostmenopausalBone Density Conservation AgentsImidazolesDiphosphonatesGonadal Steroid HormonesBone and BonesHumansZoledronic AcidFemaleMiddle AgedAgedProcollagenBiomarkersTreatment OutcomeVitamin DPeptide Fragments

Stichwörter der Autor:innen

adverse effectsblood indicatorsbone densitydenosumabmenopauseosteoporosisserumsex hormoneszoledronic acidβ‐CrossLaps

Substanzen

Zoledronic AcidDenosumabBone Density Conservation AgentsImidazolesDiphosphonatesProcollagenGonadal Steroid HormonesBiomarkersprocollagen Type I N-terminal peptideVitamin D

Autor:innen und Institutionen

  • Department of Pharmaceutical, Foresea Life Insurance Guangxi Hospital, Nanning, China.
  • Department of Endocrinology, Pu'er People's Hospital, Pu'er, China.
  • College of Basic Medical Sciences, Hubei College of Chinese Medicine, Jingzhou, China.

ORCID-Profile: Xufeng Fan

Zitieren

APA

Tang, H., Chen, J., & Fan, X. (2025). Efficacy and Safety of Denosumab and Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis—A Comparative Study of Bone Metabolism, Bone Density, and Sex Hormone Levels. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4967

Vancouver

Tang H, Chen J, Fan X. Efficacy and Safety of Denosumab and Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis—A Comparative Study of Bone Metabolism, Bone Density, and Sex Hormone Levels. Journal of Applied Toxicology. 2025. doi:10.1002/jat.4967

BibTeX
@article{Tang2025,
  author = {Tang, Huiling and Chen, Jinyan and Fan, Xufeng},
  title = {Efficacy and Safety of Denosumab and Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis—A Comparative Study of Bone Metabolism, Bone Density, and Sex Hormone Levels},
  journal = {Journal of Applied Toxicology},
  year = {2025},
  doi = {10.1002/jat.4967}
}
Kostenlos starten →